180 Life Sciences (ATNF) Competitors $2.28 -0.06 (-2.56%) (As of 11/21/2024 ET) Add Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends ATNF vs. AYTU, JAGX, ADXN, RDHL, VINC, SNGX, MBRX, ENSC, OBSV, and ATHEShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Aytu BioPharma (AYTU), Jaguar Health (JAGX), Addex Therapeutics (ADXN), RedHill Biopharma (RDHL), Vincerx Pharma (VINC), Soligenix (SNGX), Moleculin Biotech (MBRX), Ensysce Biosciences (ENSC), ObsEva (OBSV), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Aytu BioPharma Jaguar Health Addex Therapeutics RedHill Biopharma Vincerx Pharma Soligenix Moleculin Biotech Ensysce Biosciences ObsEva Alterity Therapeutics 180 Life Sciences (NASDAQ:ATNF) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends. Which has stronger earnings & valuation, ATNF or AYTU? Aytu BioPharma has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/AAytu BioPharma$81M0.11-$15.84M-$1.23-1.23 Does the MarketBeat Community prefer ATNF or AYTU? Aytu BioPharma received 253 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 66.67% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes266.67% Underperform Votes133.33% Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Do insiders and institutionals have more ownership in ATNF or AYTU? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by insiders. Comparatively, 2.8% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ATNF or AYTU more profitable? 180 Life Sciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -8.28%. Aytu BioPharma's return on equity of -21.89% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Aytu BioPharma -8.28%-21.89%-5.37% Which has more volatility & risk, ATNF or AYTU? 180 Life Sciences has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.4, indicating that its stock price is 240% less volatile than the S&P 500. Does the media refer more to ATNF or AYTU? In the previous week, Aytu BioPharma had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 6 mentions for Aytu BioPharma and 2 mentions for 180 Life Sciences. Aytu BioPharma's average media sentiment score of 0.43 beat 180 Life Sciences' score of 0.30 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAytu BioPharma beats 180 Life Sciences on 10 of the 12 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.35M$6.51B$5.09B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A6.16101.4814.96Price / SalesN/A366.491,207.9887.23Price / CashN/A52.5939.7136.27Price / Book0.6310.176.936.35Net Income-$19.93M$153.13M$118.81M$225.93M7 Day Performance-14.93%-1.61%-1.39%-0.03%1 Month Performance-54.12%-7.15%-3.29%2.00%1 Year Performance-66.67%31.67%32.29%27.82% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences0.2933 of 5 stars$2.28-2.6%N/A-66.6%$2.35MN/A0.007AYTUAytu BioPharma1.3282 of 5 stars$1.51+1.3%N/A-37.9%$9.28M$81M-1.21160JAGXJaguar Health0.6751 of 5 stars$0.97-1.0%N/A-96.5%$8.96M$9.76M0.0050ADXNAddex Therapeutics2.6652 of 5 stars$8.25+11.8%$30.00+263.6%+23.6%$8.75M$1.83M0.0030RDHLRedHill Biopharma0.975 of 5 stars$6.74+5.3%N/A-96.9%$8.63M$6.53M0.00210News CoverageVINCVincerx Pharma2.9731 of 5 stars$0.26-7.2%$2.00+681.3%-60.6%$8.59MN/A0.0060SNGXSoligenix0.9685 of 5 stars$3.39-3.4%N/A-49.0%$8.51M$840,000.00-0.4520MBRXMoleculin Biotech3.0552 of 5 stars$2.78+4.1%$31.00+1,016.3%-67.1%$8.33MN/A0.0020Analyst ForecastAnalyst RevisionENSCEnsysce Biosciences0.2193 of 5 stars$0.59-9.2%N/A-27.1%$8.22M$2.23M0.0010Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150ATHEAlterity Therapeutics3.1714 of 5 stars$1.07+1.9%$4.00+273.8%N/A$7.81MN/A0.0010Gap Up Related Companies and Tools Related Companies AYTU Competitors JAGX Competitors ADXN Competitors RDHL Competitors VINC Competitors SNGX Competitors MBRX Competitors ENSC Competitors OBSV Competitors ATHE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATNF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
